National and Kapodistrian University of Athens
Γενετική ανάλυση σε οικογένειες με ιστορικό καρκίνου μαστού και ωοθηκών με χρήση κλασσικής και επόμενης γενεάς (genomic capture) ανάλυσης του γενετικού υλικού
Abstract
dc:descriptionBreast cancer is the most common form of cancer and the leading cause of cancer-related deaths among women, both in developed and developing countries, while ovarian cancer is the eighth most common form of cancer worldwide. A percentage of 5-10% of these malignancies is explained by the presence of high, medium or low penetrance pathogenic mutations in tumor suppressor genes. Identifying such mutations in patients diagnosed with breast or ovarian cancer contributes significantly in optimizing the effectiveness of their clinical management, as well as in reducing the possibility of a new malignancy being developed in themselves or in members of their family. Beyond its clinical value, genetic analysis of hereditary breast/ovarian cancer also contributes to more efficient diagnosis and treatment through the ever-increasing understanding of the molecular mechanisms of disease progression.φThe aim of the doctoral research project presented here is the identification of mutations not only in the well-studied, highly penetrant BRCA1/2 genes, but also in a variety of other genes, which have not been analyzed to a similar depth yet. Our study cohort was comprised of a relatively large number of women diagnosed with breast or ovarian cancer, unselected for family history. The analysis initially focused on the sequencing of BRCA1 and BRCA2 genes by the Sanger method. Pathogenic mutations in the BRCA1 and BRCA2 genes were detected in 8,11% of patients. Two of these mutations are novel genetic changes that have not been recorded previously. Additionally, five missense variants of unknown clinical significance were detected. We used a variety of bioinformatic tools in order to assess their pathogenicity.RAD51C gene is another breast/ovarian cancer susceptibility gene, of medium penetrance. In the present study, a number of women diagnosed with breast or ovarian cancer were tested for a specific RAD51C mutation, (c.706-2A> G). The screening started by Real Time PCR and continued with the Next-Generation sequencing method. The aforementioned mutation was identified in thirteen female patients. Some of them also presented a family history of breast or ovarian cancer. Haplotype analysis showed that this genetic finding (c.706-2A> G) is a founder mutation for the Greek population. The gene RAD51D was also studied in the present study. The protein encoded is a member of the RAD51 protein family that plays an important role in DNA repair mechanisms. We have identified four pathogenic genetic findings and several missense variants of unknown clinical significance, subsequently studied extensively in order to evaluate their pathogenicity.Finally, DNA from 35 women were analyzed with the Trusight Cancer Gene Panel as part of the study presented in this thesis. All patients who participated in this particular cohort were diagnosed with Triple Negative Breast Cancer at the age of 35 years. 20% of these patients were found to carry pathogenic mutations in one of the BRCA1, BRCA2, ERCC3 and MUTYH genes. Additionally, missense and intronic variants of unknown clinical significance were identified in high and medium penetrance genes such as BRCA2, RAD51C, BRIP1, SLX4, RECQL4 and PALB2.Since the majority of mutant genes are involved in the homologous recombination process, these patients may benefit from new generation drugs that target homologous recombination such as PARP inhibitors.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Konstanta, Eirini
- Κωνσταντά, Ειρήνη
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44896